Gilead shares gain 35% as Biktarvy and Yeztugo drive sales growth
AI Summary- Gilead Sciences raised its full-year revenue forecast after reporting quarterly results.
- $3.8 billion was Biktarvy's quarterly revenue, according to the company disclosure.
- Twenty-three analysts rate Gilead Buy, while six assign Hold ratings.